New shigella vaccine shows promise in first human trials
NCT ID NCT05073003
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tested a new vaccine designed to protect against severe diarrhea caused by Shigella bacteria. The vaccine was first given to adults in Europe, then to adults, children, and infants in Africa. Researchers checked for side effects and measured immune responses to find the best dose for infants, who are most at risk. The trial has been completed, and results will help decide the next steps in vaccine development.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AltSonflex1-2-3 vaccine (targets Shigella sonnei and Shigella flexneri serotypes 1b, 2a, and 3a)
- What this could lead to
- If successful, this vaccine could help prevent severe, sometimes deadly diarrhea in young children in regions where Shigella is common.
- What could go wrong
- This was an early-stage trial focused on safety and immune response, not on proving the vaccine prevents disease. Larger, later-stage trials are needed to confirm effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIARRHOEA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GSK Investigational Site
Ghent, 9000, Belgium
-
GSK Investigational Site
Kericho, 20200, Kenya
More trials for these conditions
Other studies related to the condition(s) this trial covers.